Literature DB >> 27158095

Microbiome therapeutics - Advances and challenges.

Mark Mimee1, Robert J Citorik1, Timothy K Lu2.   

Abstract

The microbial community that lives on and in the human body exerts a major impact on human health, from metabolism to immunity. In order to leverage the close associations between microbes and their host, development of therapeutics targeting the microbiota has surged in recent years. Here, we discuss current additive and subtractive strategies to manipulate the microbiota, focusing on bacteria engineered to produce therapeutic payloads, consortia of natural organisms and selective antimicrobials. Further, we present challenges faced by the community in the development of microbiome therapeutics, including designing microbial therapies that are adapted for specific geographies in the body, stable colonization with microbial therapies, discovery of clinically relevant biosensors, robustness of engineered synthetic gene circuits and addressing safety and biocontainment concerns. Moving forward, collaboration between basic and applied researchers and clinicians to address these challenges will poise the field to herald an age of next-generation, cellular therapies that draw on novel findings in basic research to inform directed augmentation of the human microbiota.
Copyright © 2016. Published by Elsevier B.V.

Entities:  

Keywords:  Bacteriophage; Host-bacteria interactions; Microbial ecology; Microbiome; Synthetic biology

Mesh:

Substances:

Year:  2016        PMID: 27158095      PMCID: PMC5093770          DOI: 10.1016/j.addr.2016.04.032

Source DB:  PubMed          Journal:  Adv Drug Deliv Rev        ISSN: 0169-409X            Impact factor:   15.470


  169 in total

1.  Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells.

Authors:  Yukihiro Furusawa; Yuuki Obata; Shinji Fukuda; Takaho A Endo; Gaku Nakato; Daisuke Takahashi; Yumiko Nakanishi; Chikako Uetake; Keiko Kato; Tamotsu Kato; Masumi Takahashi; Noriko N Fukuda; Shinnosuke Murakami; Eiji Miyauchi; Shingo Hino; Koji Atarashi; Satoshi Onawa; Yumiko Fujimura; Trevor Lockett; Julie M Clarke; David L Topping; Masaru Tomita; Shohei Hori; Osamu Ohara; Tatsuya Morita; Haruhiko Koseki; Jun Kikuchi; Kenya Honda; Koji Hase; Hiroshi Ohno
Journal:  Nature       Date:  2013-11-13       Impact factor: 49.962

2.  Butyrate-producing Clostridium cluster XIVa species specifically colonize mucins in an in vitro gut model.

Authors:  Pieter Van den Abbeele; Clara Belzer; Margot Goossens; Michiel Kleerebezem; Willem M De Vos; Olivier Thas; Rosemarie De Weirdt; Frederiek-Maarten Kerckhof; Tom Van de Wiele
Journal:  ISME J       Date:  2012-12-13       Impact factor: 10.302

3.  Oral delivery of glutamic acid decarboxylase (GAD)-65 and IL10 by Lactococcus lactis reverses diabetes in recent-onset NOD mice.

Authors:  Sofie Robert; Conny Gysemans; Tatiana Takiishi; Hannelie Korf; Isabella Spagnuolo; Guido Sebastiani; Karolien Van Huynegem; Lothar Steidler; Silvia Caluwaerts; Pieter Demetter; Clive H Wasserfall; Mark A Atkinson; Francesco Dotta; Pieter Rottiers; Tom L Van Belle; Chantal Mathieu
Journal:  Diabetes       Date:  2014-03-27       Impact factor: 9.461

4.  Inducible Foxp3+ regulatory T-cell development by a commensal bacterium of the intestinal microbiota.

Authors:  June L Round; Sarkis K Mazmanian
Journal:  Proc Natl Acad Sci U S A       Date:  2010-06-21       Impact factor: 11.205

5.  Delivery mode shapes the acquisition and structure of the initial microbiota across multiple body habitats in newborns.

Authors:  Maria G Dominguez-Bello; Elizabeth K Costello; Monica Contreras; Magda Magris; Glida Hidalgo; Noah Fierer; Rob Knight
Journal:  Proc Natl Acad Sci U S A       Date:  2010-06-21       Impact factor: 11.205

6.  Human genetics shape the gut microbiome.

Authors:  Julia K Goodrich; Jillian L Waters; Angela C Poole; Jessica L Sutter; Omry Koren; Ran Blekhman; Michelle Beaumont; William Van Treuren; Rob Knight; Jordana T Bell; Timothy D Spector; Andrew G Clark; Ruth E Ley
Journal:  Cell       Date:  2014-11-06       Impact factor: 41.582

7.  In vivo replication of T4 and T7 bacteriophages in germ-free mice colonized with Escherichia coli.

Authors:  Marietta Weiss; Emmanuel Denou; Anne Bruttin; Ruth Serra-Moreno; Marie-Lise Dillmann; Harald Brüssow
Journal:  Virology       Date:  2009-08-21       Impact factor: 3.616

8.  Bacteriophage adhering to mucus provide a non-host-derived immunity.

Authors:  Jeremy J Barr; Rita Auro; Mike Furlan; Katrine L Whiteson; Marcella L Erb; Joe Pogliano; Aleksandr Stotland; Roland Wolkowicz; Andrew S Cutting; Kelly S Doran; Peter Salamon; Merry Youle; Forest Rohwer
Journal:  Proc Natl Acad Sci U S A       Date:  2013-05-20       Impact factor: 11.205

Review 9.  Short-chain fatty acids in control of body weight and insulin sensitivity.

Authors:  Emanuel E Canfora; Johan W Jocken; Ellen E Blaak
Journal:  Nat Rev Endocrinol       Date:  2015-08-11       Impact factor: 43.330

10.  Exploiting CRISPR-Cas nucleases to produce sequence-specific antimicrobials.

Authors:  David Bikard; Chad W Euler; Wenyan Jiang; Philip M Nussenzweig; Gregory W Goldberg; Xavier Duportet; Vincent A Fischetti; Luciano A Marraffini
Journal:  Nat Biotechnol       Date:  2014-10-05       Impact factor: 54.908

View more
  57 in total

Review 1.  Development of bacteria as diagnostics and therapeutics by genetic engineering.

Authors:  Daejin Lim; Miryoung Song
Journal:  J Microbiol       Date:  2019-05-11       Impact factor: 3.422

Review 2.  Complementary and Alternative Medicine Strategies for Therapeutic Gut Microbiota Modulation in Inflammatory Bowel Disease and their Next-Generation Approaches.

Authors:  Abigail R Basson; Minh Lam; Fabio Cominelli
Journal:  Gastroenterol Clin North Am       Date:  2017-12       Impact factor: 3.806

Review 3.  Precision Medicine Goes Microscopic: Engineering the Microbiome to Improve Drug Outcomes.

Authors:  Kathy N Lam; Margaret Alexander; Peter J Turnbaugh
Journal:  Cell Host Microbe       Date:  2019-07-10       Impact factor: 21.023

Review 4.  Modulation of Type 1 Diabetes Risk by the Intestinal Microbiome.

Authors:  Mikael Knip; Jarno Honkanen
Journal:  Curr Diab Rep       Date:  2017-09-23       Impact factor: 4.810

Review 5.  Community profiling of the urinary microbiota: considerations for low-biomass samples.

Authors:  Lisa Karstens; Mark Asquith; Vincent Caruso; James T Rosenbaum; Damien A Fair; Jonathan Braun; W Thomas Gregory; Rahel Nardos; Shannon K McWeeney
Journal:  Nat Rev Urol       Date:  2018-12       Impact factor: 14.432

6.  Successive passaging of a plant-associated microbiome reveals robust habitat and host genotype-dependent selection.

Authors:  Norma M Morella; Francis Cheng-Hsuan Weng; Pierre M Joubert; C Jessica E Metcalf; Steven Lindow; Britt Koskella
Journal:  Proc Natl Acad Sci U S A       Date:  2019-12-05       Impact factor: 11.205

7.  Engineered bacteria can function in the mammalian gut long-term as live diagnostics of inflammation.

Authors:  David T Riglar; Tobias W Giessen; Michael Baym; S Jordan Kerns; Matthew J Niederhuber; Roderick T Bronson; Jonathan W Kotula; Georg K Gerber; Jeffrey C Way; Pamela A Silver
Journal:  Nat Biotechnol       Date:  2017-05-29       Impact factor: 54.908

Review 8.  To engraft or not to engraft: an ecological framework for gut microbiome modulation with live microbes.

Authors:  Jens Walter; María X Maldonado-Gómez; Inés Martínez
Journal:  Curr Opin Biotechnol       Date:  2017-09-13       Impact factor: 9.740

Review 9.  Microbiota and metabolic diseases.

Authors:  Alessia Pascale; Nicoletta Marchesi; Cristina Marelli; Adriana Coppola; Livio Luzi; Stefano Govoni; Andrea Giustina; Carmine Gazzaruso
Journal:  Endocrine       Date:  2018-05-02       Impact factor: 3.633

10.  Genetic Engineering of Bee Gut Microbiome Bacteria with a Toolkit for Modular Assembly of Broad-Host-Range Plasmids.

Authors:  Sean P Leonard; Jiri Perutka; J Elijah Powell; Peng Geng; Darby D Richhart; Michelle Byrom; Shaunak Kar; Bryan W Davies; Andrew D Ellington; Nancy A Moran; Jeffrey E Barrick
Journal:  ACS Synth Biol       Date:  2018-04-13       Impact factor: 5.110

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.